Insights on mid-term TAVR performance: 3-year clinical and echocardiographic results from the CoreValve ADVANCE study
ConclusionsOur 3-year data demonstrate significant hemodynamic benefits and durable symptom relief after CoreValve prosthesis implantation. Postprocedural patient management should be carefully considered, since postprocedural valve-related events were identified as independent predictors of mid-term mortality.Trial registration ClinicalTrials.gov, NCT01074658.
Source: Clinical Research in Cardiology - Category: Cardiology Source Type: research
More News: Aortic Stenosis | Atrial Fibrillation | Bleeding | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Chronic Obstructive Pulmonary | Heart | Heart Valve Surgery | Stroke | Study